Antimicrobials
Voriconazole

Voriconazole

Low
Excellent

Spectrum of Activity

General Information

Preparation

  • Reconstitute vials with sterile water (SWFI)
  • Dilute for IV administration in NS, LR, or D5W to final concentration of 5 mg/ml or less

Administration

  • Infuse over 1 to 3 hours (rate not to exceed 3 mg/kg/hour). Do not infuse concomitantly into same line with other drug infusions.

Diluent

  • NS, LR, D5LR, D5W, D5-0.45%NaCl, D5-0.9%NaCl, 0.45%NaCl, or D5W/20 mEq potassium chloride
  • Candida infections both mucocutaneous and invasive - i.e. Candidemia.
  • Antifungal prophylaxis in immunocompromised patients.
  • Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (Discuss with ID).
  • QTc interval in patients at elevated risk.
  • Monitor hepatic profile.
  • Drug interactions
  • QTc prolongation
  • Hepatic enzyme abnormalities
  • Rash - up to 20%
  • Visual disturbance
  • Fluorosis
  • GI upset
  • CYP450 interactions ++.
  • Other QTc prolonging agents.
  • Recommend review of pt medications due to high frequency of significant interactions.

Antimicrobial class: Triazole antifungal, Second generation

Pregnancy category: D

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Therapeutic